How Does Masimo Company Work and What Drives Its Business Model?

Masimo company's flagship is Signal Extraction Technology (SET) pulse oximetry for accurate SpO2 under motion and low perfusion. The Rainbow sensor line adds noninvasive hemoglobin (SpHb), carboxyhemoglobin, methemoglobin, and acoustic respiration rate on the same sensor. Root acts as the clinical hub that aggregates these signals and routes them to electronic medical records.

Buyers are hospitals, outpatient clinics, and ambulatory surgery centers purchasing monitors and recurring disposable sensors; procurement and clinical engineering teams buy hardware, while IT and informatics buy integration and SaaS services. Emergency services and specialty practices also procure sensors for point-of-care diagnostics.

Clinicians get continuous, actionable physiologic data that reduces false alarms and improves detection of hypoxemia and bleeding (noninvasive hemoglobin), lowering intervention time. Hospitals gain device-to-EMR integration, inventory predictability via consumable sensor revenue, and potential reductions in length of stay and adverse events.

Masimo business model ties proprietary SET and Rainbow sensors to Root and cloud services, creating recurring revenue from disposables and SaaS. The noninvasive measurements (no needle sticks) and proven performance versus competitors such as Nellcor and Philips drive clinical adoption and licensing opportunities; see Growth Outlook of Masimo Company for additional context.

Masimo medical technology earns most revenue from sensors and consumables sold repeatedly to hospitals; these high-volume items make up roughly ~80 percent of healthcare sales and drive steady cash flow.

Secondary streams include sale or subsidized placement of monitoring hardware, software subscriptions, service contracts, and licensing/royalties for pulse oximetry technology and integrations with hospital systems.

Masimo often provides monitors at low upfront cost or under multi-year contracts (five to seven years) to lock hospitals into recurring purchases of proprietary sensors, converting installed base into a subscription-like revenue stream.

As long as hospital beds are occupied, Masimo generates cash because each monitored patient consumes sensors; healthcare revenues in early 2026 are around $1.4 billion – $1.5 billion annually with gross margins in the medical segment above 65 percent.

Once hospitals integrate Masimo medical technology into workflows and IT systems, retraining, validation, and procurement cycles create high switching costs that support durable recurring revenue from sensors and consumables. Integrated alerts, clinical validation studies, and device interoperability deepen customer dependence on Masimo's noninvasive patient monitoring tools.

Masimo's patents and algorithms for how Masimo pulse oximetry works provide a defensible moat versus competitors like Nellcor and Philips; clinical-grade accuracy is a barrier to entry for consumer-focused big-tech entrants. Robust FDA history and regulatory approvals underpin hospital adoption and reimbursement pathways.

Masimo revenue streams remain concentrated in hospital channels and recurring sensor sales, with 8 – 10% organic growth guidance after the consumer separation. Dependence on hospital capital budgets, reimbursement trends, and a limited number of large health-system customers are material concentration risks.

Management's 2025 plan to separate the consumer audio business restores focus to Masimo business model and should lift gross margins toward med-tech peers as lower-margin consumer lines are divested. Execution speed matters: slower separation delays margin recovery and prolongs activist scrutiny; faster cleanup accelerates return to core growth and recurring royalties.